SWOG 0514: A phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1646-1651

  El Khoueiry, Anthony B ^a   Rankin, Cathryn J ^b   Ben Josef, Edgar ^c   Lenz, Heinz Josef ^a   Gold, Philip J ^d   Hamilton, R Darryl ^e   Govindarajan, Rangaswamy ^f   Eng, Cathy ^g   Blanke, Charles D ^h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d SWEDISH MEDICAL CENTER   (United States)

^e UNIVERSITY OF MISSISSIPPI   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Sorafenib

Indexed keywords

SORAFENIB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GALLBLADDER CARCINOMA; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; LUNG EMBOLISM; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRIDINES; TREATMENT OUTCOME;

EID: 84866729534     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9719-0     Document Type: Article

References (22)

1. Cardinale V et al (2010) Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol 2(11):407-16
2. McGlynn KA, Tarone RE, El-Serag HB (2006) A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 15(6):1198-203
3. Hezel AF, Zhu AX (2008) Systemic therapy for biliary tract cancers. Oncologist 13(4):415-23
4. Choi CW et al (2000) Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 23(4):425-8
5. Ducreux M et al (2005) A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 41(3):398-403
6. Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96 (6):896-902
7. Valle J et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273-81
8. Tannapfel A et al (2003) Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52 (5):706-12
9. Yoon JH et al (2002) Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 62(22):6500-5
10. Benckert C et al (2003) Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63(5):1083-92
11. Yoshikawa D et al (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98(2):418-25
12. Wilhelm SM et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-109
13. Green SJ, Dahlberg S (1992) Planned versus attained design in phase II clinical trials. Stat Med 11(7):853-62
14. Blechacz BR et al (2009) Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 50 (6):1861-70
15. Sugiyama H et al (2011) Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. J Gastroenterol
16. Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-90
17. Iqbal S, Blanke C, Lenz HJ (2006) SWOG S0202: A phase II trial of gemcitabine and capecitabine in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinoma. Abstract # 4131. in Proceedings of the American Society of Clinical Oncology
18. Bengala C et al (2010) Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 102(1):68-72
19. Yonemoto N et al (2007) A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 37(11):843-51
20. Nehls O et al (2008) Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 98 (2):309-15
21. Harder J et al (2006) Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 95 (7):848-52
22. Jarnagin WR et al (2006) Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 24 (7):1152-60